Non-Absorbable Oral Gentamicin Sulphate: Biopharmaceutical and Dosage Form Evaluation

[1] Pignatello, R.; Simerska, P.; Leonardi, A.; Abdelrahim, A.S; Petronio, G.P.; Fuochi, V.; Furneri, P.M.; Ruozi B.; Toth I. Synthesis, characterization and in vitro evaluation of amphiphilic ion pairs of erythromycin and kanamycin antibiotics with liposaccharides. Eur J Med Chem., 2016, 120,329–337. PignatelloR. SimerskaP. LeonardiA. AbdelrahimA.S. PetronioG.P. FuochiV. FurneriP.M. RuoziB. TothI. Synthesis, characterization and in vitro evaluation of amphiphilic ion pairs of erythromycin and kanamycin antibiotics with liposaccharides Eur J Med Chem. 2016 120 329 337 10.1016/j.ejmech.2016.04.074 Search in Google Scholar

[2] Baasov, T.; Atia-Glikin, D.; Kandasamy, J.; Belakhov, V. Technion Research and Development Foundation Ltd, 2015. Aminoglycosides and uses thereof in treating genetic disorders. U.S. Patent 9,175,029. BaasovT. Atia-GlikinD. KandasamyJ. BelakhovV. Technion Research and Development Foundation Ltd 2015 Aminoglycosides and uses thereof in treating genetic disorders U.S. Patent 9,175,029. Search in Google Scholar

[3] Ito, Y.; Kusawake, T.; Ishida, M.; Tawa, R.; Shibata, N.; Takada, K. Oral solid gentamicin preparation using emulsifier and adsorbent. J Controlled Release, 2005,105(1–2),23–31. ItoY. KusawakeT. IshidaM. TawaR. ShibataN. TakadaK. Oral solid gentamicin preparation using emulsifier and adsorbent J Controlled Release 2005 105 1–2 23 31 10.1016/j.jconrel.2005.03.017 Search in Google Scholar

[4] Imamura, S.; Adams, J.C. Distribution of gentamicin in the guinea pig inner ear after local or systemic application. JARO, 2003, 04, 176–195. ImamuraS. AdamsJ.C. Distribution of gentamicin in the guinea pig inner ear after local or systemic application JARO 2003 04 176 195 10.1007/s10162-002-2036-8 Search in Google Scholar

[5] Labiris, N.R.C.; Holbrook, A.M.; Chrystyn, H.; Macleod, S.M.; Newhouse, M.T. Dry powder versus intravenous and nebulized gentamicin in cystic Fibrosis and bronchiectasis; a pilot study. Am J Respir Crit Care Med 1999, 160(5), 1711–1716. LabirisN.R.C. HolbrookA.M. ChrystynH. MacleodS.M. NewhouseM.T. Dry powder versus intravenous and nebulized gentamicin in cystic Fibrosis and bronchiectasis; a pilot study Am J Respir Crit Care Med 1999 160 5 1711 1716 10.1164/ajrccm.160.5.9810080 Search in Google Scholar

[6] Ipsen, T.; Jørgensen, P.S.; Damholt, V.; Tørholm, C. Gentamicin-collagen sponge for local applications: 10 cases of chronic osteomyelitis followed for 1 year. Acta OrthopScand., 1991, 62(6), 592–594. IpsenT. JørgensenP.S. DamholtV. TørholmC. Gentamicin-collagen sponge for local applications: 10 cases of chronic osteomyelitis followed for 1 year Acta OrthopScand. 1991 62 6 592 594 10.3109/17453679108994503 Search in Google Scholar

[7] Nnamani, P.O.; Kenechukwu, F.C.; Dibua, E.U.; Ogbonna, C.C.; Momoh, M.A.; 1, Olisemeka, A.U.; Obumneme, A.C.; Attama, A.A. Formulation, characterization and ex-vivo permeation studies on gentamicin-loaded transdermal patches based on PURASORB^® polymers Sci Res Essays. 2013, 8(22), 973–982 NnamaniP.O. KenechukwuF.C. DibuaE.U. OgbonnaC.C. MomohM.A. OlisemekaA.U. ObumnemeA.C. AttamaA.A. Formulation, characterization and ex-vivo permeation studies on gentamicin-loaded transdermal patches based on PURASORB^® polymers Sci Res Essays 2013 8 22 973 982 Search in Google Scholar

[8] Pick, J.; Olson, L.L.; Ellis, W.Y.; Lim, P. Development and validation of a method to extract and quantitate paromomycin and gentamicin from an aquaphilic cream formulation. J Pharm Biomed Anal., 1997; 16, 131–137. PickJ. OlsonL.L. EllisW.Y. LimP. Development and validation of a method to extract and quantitate paromomycin and gentamicin from an aquaphilic cream formulation J Pharm Biomed Anal. 1997 16 131 137 10.1016/S0731-7085(96)02044-4 Search in Google Scholar

[9] Ravis, W.R.; Llanos-Cuentas, A.; Sosa, N. Kreishman-Deitrick, M.; Kopydlowski, K.M.; Nielsen, C.; Smith, K.S.; Smith, P.L.; Ransom, J.H.; Lin Y-J.; Grogl M. Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis. Antimicrob. Agents Chemother. 2013, 57(10), 4809–4815. RavisW.R. Llanos-CuentasA. SosaN. Kreishman-DeitrickM. KopydlowskiK.M. NielsenC. SmithK.S. SmithP.L. RansomJ.H. LinY-J. GroglM. Pharmacokinetics and absorption of paromomycin and gentamicin from topical creams used to treat cutaneous leishmaniasis Antimicrob. Agents Chemother. 2013 57 10 4809 4815 10.1128/AAC.00628-13 Search in Google Scholar

[10] Aquino, R.P.; Prota, L.; Auriemma, G.; Santoro, A.; Mencherini, T.; Colombo, G.; Russo, P. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells. Int J Pharm., 2012, 426, 100–107. AquinoR.P. ProtaL. AuriemmaG. SantoroA. MencheriniT. ColomboG. RussoP. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells Int J Pharm 2012 426 100 107 10.1016/j.ijpharm.2012.01.026 Search in Google Scholar

[11] Goldman, J.M., Bayston, S.M.; O’Connor, S., Meigh, R.E. Inhaled micronised gentamicin powder: a new delivery system. Thorax., 1990; 45:939–940. GoldmanJ.M. BaystonS.M. O’ConnorS. MeighR.E. Inhaled micronised gentamicin powder: a new delivery system Thorax 1990 45 939 940 10.1136/thx.45.12.939 Search in Google Scholar

[12] Lim, S.T.; Forbes, B.; Berry, D.J.; Martin, G.P.; Brown, M.B. In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits. Int J Pharm. 2002, 231:73–82. LimS.T. ForbesB. BerryD.J. MartinG.P. BrownM.B. In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits Int J Pharm 2002 231 73 82 10.1016/S0378-5173(01)00873-0 Search in Google Scholar

[13] Fix, J.A.; Porter, P.A.; Leppert, P.S. Involvement of active sodium transport in the rectal absorption of gentamicin sulfate in the presence and absence of absorption-promoting adjuvants. J Pharm Sci., 1983, 72(6), 698–700. FixJ.A. PorterP.A. LeppertP.S. Involvement of active sodium transport in the rectal absorption of gentamicin sulfate in the presence and absence of absorption-promoting adjuvants J Pharm Sci 1983 72 6 698 700 10.1002/jps.2600720626 Search in Google Scholar

[14] Krasko, M.Y.; Golenser, J.; Nyska, A.; Nyska, M., Brin, Y.S.; Domb, A.J. Gentamicin extended release from an injectable polymeric implant. J Control Release. 2007; 117:90–96. KraskoM.Y. GolenserJ. NyskaA. NyskaM. BrinY.S. DombA.J. Gentamicin extended release from an injectable polymeric implant J Control Release 2007 117 90 96 10.1016/j.jconrel.2006.10.010 Search in Google Scholar

[15] Soriano, I.; Evora, C. Formulation of calcium phosphates/poly (d, l-lactide) blends containing gentamicin for bone implantation. J Controlled Release, 2000, 68, 121–134. SorianoI. EvoraC. Formulation of calcium phosphates/poly (d, l-lactide) blends containing gentamicin for bone implantation J Controlled Release 2000 68 121 134 10.1016/S0168-3659(00)00251-0 Search in Google Scholar

[16] Rama Prasad, Y.V.; Eaimtrakarn, S.; Ishida, M.; Kusawake, Y.; Tawa, R.; Yoshikawa, Y.; Shibata, N.; Takada, K. Evaluation of oral formulations of gentamicin containing labrasol in beagle dogs. Inter J Pharmaceut., 2003, 268, 13–21. Rama PrasadY.V. EaimtrakarnS. IshidaM. KusawakeY. TawaR. YoshikawaY. ShibataN. TakadaK. Evaluation of oral formulations of gentamicin containing labrasol in beagle dogs Inter J Pharmaceut 2003 268 13 21 10.1016/j.ijpharm.2003.08.00814643972 Search in Google Scholar

[17] Gephart, SM., McGrath, JM., Effken, JA. and Halpern, MD. (2012). Necrotizing Enterocolitis Risk. Adv Neonatal Care, 12(2): 77–89. doi: 10.1097/ANC.0b013e31824cee94 GephartSM. McGrathJM. EffkenJA. HalpernMD. 2012 Necrotizing Enterocolitis Risk Adv Neonatal Care 12 2 77 89 10.1097/ANC.0b013e31824cee94 335763022469959 Open DOISearch in Google Scholar

[18] Shah D and Sinn JK. (2012). Antibiotic regimens for the empirical treatment of newborn infants with necrotising enterocolitis. Cochrane Database Syst Rev. 15; 8:CD007448. doi: 10.1002/14651858.CD007448.pub2. ShahD SinnJK 2012 Antibiotic regimens for the empirical treatment of newborn infants with necrotising enterocolitis Cochrane Database Syst Rev 15 8 CD007448. 10.1002/14651858.CD007448.pub2 22895960 Open DOISearch in Google Scholar

[19] Verma, K., Gupta, A.B. and Singh, A., (2014). Optimization of Chlorination Process and Analysis of. Water Sci, 4(3), 231–239. VermaK. GuptaA.B. SinghA. 2014 Optimization of Chlorination Process and Analysis of Water Sci 4 3 231 239 Search in Google Scholar

[20] Anilkumar, P.; Badarinath, A.V.; Naveen, N.; Nirosha, M. A rationalized description on study of intestinal barrier, drug permeability and permeation enhancers. J Global Trends Pharma Sci., 2011, 2(4), 431–449. AnilkumarP. BadarinathA.V. NaveenN. NiroshaM. A rationalized description on study of intestinal barrier, drug permeability and permeation enhancers J Global Trends Pharma Sci. 2011 2 4 431 449 Search in Google Scholar

[21] Shaikh, M.S.; Derle, N.D.; Bhamber, R. Permeability enhancement techniques for poorly permeable drugs: a review. JAPS 2012, 02(06), 34–39. ShaikhM.S. DerleN.D. BhamberR. Permeability enhancement techniques for poorly permeable drugs: a review JAPS 2012 02 06 34 39 10.7324/JAPS.2012.2705 Search in Google Scholar

[22] Umeyor, C.; Attama, A.; Uronnachi, E.; Kenechukwu, F.; Nwakile, C.; Nzekwe, I.; Okoye, E.; Esimone, C. Formulation design and in vitro physicochemical characterization of surface modified self-nanoemulsifying formulations (SNEFs) of gentamicin. Inter J Pharmaceut 2016; 497:161–98. UmeyorC. AttamaA. UronnachiE. KenechukwuF. NwakileC. NzekweI. OkoyeE. EsimoneC. Formulation design and in vitro physicochemical characterization of surface modified self-nanoemulsifying formulations (SNEFs) of gentamicin Inter J Pharmaceut 2016 497 161 98 10.1016/j.ijpharm.2015.10.03326657350 Search in Google Scholar

[23] Walker, M.M.; Talley, N.J. Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract – beyond the era of Helicobacter pylori. Aliment Pharm Ther., 2014; 39(8), 767–779. WalkerM.M. TalleyN.J. Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract – beyond the era of Helicobacter pylori Aliment Pharm Ther. 2014 39 8 767 779 10.1111/apt.1266624612362 Search in Google Scholar

[24] Nwakile, C.D. Production, Characterization and Application of Multiple Modified Maize Starches in the Formulation of Oral Solid Dosage Forms of Gentamicin Sulphate. A thesis submitted to the Department of Pharmaceutics in partial fulfilment for the award of doctor of philosophy (Ph.D) of the University of Nigeria, Nsukka, Enugu State, Nigeria. 2017. Available at: http://dspace.unn.edu.ng/bitstream/handle/123456789/5494/Nwakile%2C%20Calistus%20Dozie.pdf?sequence=1&isAllowed=y, Accessed February 20, 2020. NwakileC.D. Production, Characterization and Application of Multiple Modified Maize Starches in the Formulation of Oral Solid Dosage Forms of Gentamicin Sulphate A thesis submitted to the Department of Pharmaceutics in partial fulfilment for the award of doctor of philosophy (Ph.D) of the University of Nigeria Nsukka, Enugu State, Nigeria 2017 Available at: http://dspace.unn.edu.ng/bitstream/handle/123456789/5494/Nwakile%2C%20Calistus%20Dozie.pdf?sequence=1&isAllowed=y, Accessed February 20, 2020. Search in Google Scholar

[25] Canadian Pharmaceutical Association Compendium of Pharmaceuticals and Specialities, the Canadian drug reference for health professionals. Webcom limited, Toronto, 2002. Canadian Pharmaceutical Association Compendium of Pharmaceuticals and Specialities, the Canadian drug reference for health professionals Webcom limited Toronto 2002 Search in Google Scholar

[26] EMEA. Gentamicin: Summary report (3) - Committee for Veterinary Medicinal Products EMEA/MRL/803/01-final November 2001. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_Report/2009/11/WC500014350.pdf.. Accessed March 2, 2020. EMEA Gentamicin: Summary report (3) - Committee for Veterinary Medicinal Products EMEA/MRL/803/01-final November 2001 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_Report/2009/11/WC500014350.pdf.. Accessed March 2, 2020. Search in Google Scholar

[27] Kibbe AH. Hand book of Pharmaceutical excipients, 3rd ed. Washington: American Pharmaceutical Association and Pharmaceutical Press; 2000. KibbeAH Hand book of Pharmaceutical excipients 3rd ed. Washington American Pharmaceutical Association and Pharmaceutical Press 2000 Search in Google Scholar